Developers: | MEZ, Moscow Endocrine Plant (Endopharm) |
Last Release Date: | 2022/12/02 |
Branches: | Pharmaceuticals, Medicine, Healthcare |
2022: Obtaining a marketing authorization
FSUE "Moscow Endocrine Plant" (FSUE "Endopharm") received a registration certificate for a veterinary drug for general anesthesia. This was announced on December 2, 2022 by the head of the Department of Investment and Industrial Policy of Moscow, which is part of the Complex of Economic Policy and Property and Land Relations of the capital, Vladislav Ovchinsky.
Metropolitan industrialists successfully continue to develop the production of goods for animals, including in the field of pharmaceuticals. Thus, the Moscow Endocrine Plant received a registration certificate for a drug for non-oral general anesthesia for cats and dogs. The medicine became the second veterinary drug in the assortment of the enterprise. As of December 2022, the regions collect applications from veterinary hospitals for the purchase of this drug, - said Vladislav Ovchinsky. |
All submitted applications will be submitted to the Ministry of Industry and Trade of Russia to further take into account the need for veterinary hospitals when distributing the drug to them.
This medicinal product for veterinary use with international non-proprietary name (INN) ketamine is developed in the form of a solution for injection and is available in vials. The drug is intended only for use by veterinary specialists in hospital settings.
Earlier, FSUE Endopharm brought to the domestic market a veterinary painkiller veterinary drug with the international non-proprietary name Tramadol.
In November 2022, the Moscow Endocrine Plant confirmed the high quality standards of manufactured veterinary drugs, having received a conclusion on the compliance of the manufacturer of medicines for veterinary use with the GMP requirements of the Eurasian Economic Union.
In addition, a special section has been created on the company's website for specialists in the field of veterinary medicine, where they can consult with experts from FSUE Endopharm on the turnover of manufactured veterinary drugs.